With a Goldilocks economy and a bull market charging into a second year, 2024 shaped up to be a good year for investors. Now, ...

Loomis Sayles, an investment management company, released its “International Growth Fund” third quarter 2024 investor letter.

The pharmaceutical industry in Denmark has grown rapidly in recent years. This paper discusses the macroeconomic impact of the pharmaceutical sector. The analysis focuses on Novo Nordisk, the leading ...

The largest project underway is Novo Nordisk’s $4.1 billion expansion in Johnston County ... Amgen is also growing its local ...

Shares in Ozempic maker Novo Nordisk tumbled after an experimental anti-obesity shot fell short of expectations. The shares fell more than 20% in Copenhagen, closing at their lowest since August 2023.

Illustration: Elizabeth Smelov Novo Nordisk’s big bet to improve on the success of its weight-loss drug franchise hit a ...

Eli Lilly, a competitor in the market for GLP-1 weight loss drugs, was up about 5%. Novo Nordisk's stock suffered its biggest one-day slide on record after its latest obesity drug trial ...

Stocks signaled another rough day of trading on Friday after the House of Representatives voted against a Trump-backed ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

Novo Nordisk (NVO) stock dropped more than 15% on Friday following an update on its obesity drug that fell short of expectations. Headlines from the company’s press release revealed that Novo ...

Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more effective ...